Хайлтын үр дүнгүүд - Karim Iskander

  • 8-н 1 - 8 үр дүнгүүдийг харуулж байна
Үр дүнг сайжруулах
  1. 1
    Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes

    Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes -н Ola Landgren, Karim Iskander

    Хэвлэсэн 2017
    Бүрэн текст авах Бүрэн текст авах
    Revisão
    Жагсаалт руу хадгалах
    -д хадгалсан:
  2. 2
    NRH:Quinone Oxidoreductase 2 and NAD(P)H:Quinone Oxidoreductase 1 Protect Tumor Suppressor p53 against 20S Proteasomal Degradation Leading to Stabilization and Activation of p53

    NRH:Quinone Oxidoreductase 2 and NAD(P)H:Quinone Oxidoreductase 1 Protect Tumor Suppressor p53 against 20S Proteasomal Degradation Leading to Stabilization and Activation of p53 -н Xing Gong, Labanyamoy Kole, Karim Iskander, Anil K. Jaiswal

    Хэвлэсэн 2007
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  3. 3
    NQO1 and NQO2 Regulation of Humoral Immunity and Autoimmunity

    NQO1 and NQO2 Regulation of Humoral Immunity and Autoimmunity -н Karim Iskander, Jessica Li, Shuhua Han, Biao Zheng, Anil K. Jaiswal

    Хэвлэсэн 2006
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  4. 4
    Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma

    Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma -н Ola Landgren, Pieter Sonneveld, Andrzej Jakubowiak, Mohamad Mohty, Karim Iskander, Khalid Mezzi, David S. Siegel

    Хэвлэсэн 2019
    Бүрэн текст авах Бүрэн текст авах
    Revisão
    Жагсаалт руу хадгалах
    -д хадгалсан:
  5. 5
    Disruption of Dihydronicotinamide Riboside:Quinone Oxidoreductase 2 (NQO2) Leads to Myeloid Hyperplasia of Bone Marrow and Decreased Sensitivity to Menadione Toxicity

    Disruption of Dihydronicotinamide Riboside:Quinone Oxidoreductase 2 (NQO2) Leads to Myeloid Hyperplasia of Bone Marrow and Decreased Sensitivity to Menadione Toxicity -н Delwin J. Long, Karim Iskander, Amos Gaikwad, Meral J. Arin, Dennis R. Roop, Richard J. Knox, Roberto Barrios, Anil K. Jaiswal

    Хэвлэсэн 2002
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  6. 6
    The BiTE (bispecific T‐cell engager) platform: Development and future potential of a targeted immuno‐oncology therapy across tumor types

    The BiTE (bispecific T‐cell engager) platform: Development and future potential of a targeted immuno‐oncology therapy across tumor types -н Hermann Einsele, Hossein Borghaei, Robert Z. Orlowski, Marion Subklewe, Gail J. Roboz, Gerhard Zugmaier, Peter Kufer, Karim Iskander, Hagop M. Kantarjian

    Хэвлэсэн 2020
    Бүрэн текст авах Бүрэн текст авах
    Revisão
    Жагсаалт руу хадгалах
    -д хадгалсан:
  7. 7
    Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVOR

    Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVOR -н Meletios Α. Dimopoulos, David S. Siegel, Darrell White, Ralph V. Boccia, Karim Iskander, Zhao Yang, Amy Kimball, Khalid Mezzi, Heinz Ludwig, Rubén Niesvizky

    Хэвлэсэн 2018
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  8. 8
    Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials

    Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials -н Ajai Chari, A. Keith Stewart, Stuart D. Russell, Philippe Moreau, Joerg Herrmann, José Banchs, Roman Hájek, John D. Groarke, Alexander R. Lyon, George N. Batty, Sunhee Ro, Mei Huang, Karim Iskander, Daniel J. Lenihan

    Хэвлэсэн 2018
    Бүрэн текст авах
    Revisão
    Жагсаалт руу хадгалах
    -д хадгалсан:

Хайх хэрэгслүүд: